Bosco & Crossy's stock picks,talk area Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Crossy who wrote (4526)	1/7/2004 8:30:58 AM
From: Crossy	of 37387

re : 0399.HK - Far East Pharmaceutical (HongKong) - HK$ 1.07 I did some search for new literature on the web and found another great research report from Core/Yamaichi analyst Jeff Wong - this time on Far East Pharma.. He maintains his BUY rating of FE Pharma (0399.HK) with a target price of HK$1.20 ---- iprasia.com He especially outlines the midterm strategy - I long suspected something like that given the background of the still very fragmented PRC pharma market, FE Pharma's huge cash position (more than $700m HK$ if my calculations are correct) and the recently tigthened chinese cGMP standards, which will drive many fringe producers out of the market due to the costs associated with facilities upgrades highlights: - 0399.HK - FE Pharma has 270 drugs in its product portfolio - 4 drugs launched this year and contributed 14% to total revenue" - growth strategy is to acquire quality assets and best selling drugs, firm plans to spend HK$300m over 3 years to acquire 30 companies - PRC pharma market still fragmented, biggest firm accounting for 3% of revenue - diversified product mix will help reduce risk and boost revenue stream now if this doesn't sound good then I don't know what does CROSSY

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next